REYKJAVIK, Iceland, Aug. 30, 2005 (PRIMEZONE) -- The Actavis Group today announces that it has made organizational changes within its Sales and Marketing International division (Own-label sales) and appointed a new Chief Executive for the division. The change is designed to consolidate the sales and marketing team with the Actavis' Icelandic headquarters. Sigurdur Oli Olafsson (37), currently the Chief Executive of Corporate Development, will take on the role of Chief Executive of Sales and Marketing International from 1 September.
Olafsson will be responsible for the management of the Sales and Marketing division, including Global Market Information and In-licensing. Olafsson, a Pharmacist from the University of Iceland, joined Actavis in 2003 after working for Pfizer UK from 1998 and then Pfizer in the US from 2001 where he worked in Global Research and Development. Previously Olafsson served as Marketing Manager for an Actavis subsidiary, later becoming Drug Development Manager.
Per Edelmann, currently Chief Executive of Sales and Marketing International, will leave the company as of 1 September to take on other responsibilities. Edelmann will continue to work for Actavis for the next few months.
The responsibilities of the Corporate Development will be integrated into Sales and Marketing International, Research and Development and Finance division.
The Executive Board would like to take this opportunity to thank Per for his contribution and extend their best wishes for the future.
For further information please contact:
Halldor Kristmannsson Director of Corporate Communications Tel: +354 535 2300 / 354 840 3425 hkristmannsson@actavis.com
-0-